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A B S T R A C T
Background: The magnitude of clinical beneﬁt scale (MCBS) was introduced by the European Society of Medical
Oncology (ESMO) to quantify the clinical beneﬁt of therapeutic regimens and to prioritise therapies. It distin-
guishes curative from palliative treatments and ranks their beneﬁt based on overall survival (OS), progression
free survival (PFS), quality of life (QoL) and toxicity. Objective of this study on the ﬁrst line treatment of ovarian
cancer was to evaluate the evidence for the current standard of care using the ESMO-MCBSv1.1 with an em-
phasis on controversial therapeutic options: intraperitoneal chemotherapy, dose-dense paclitaxel and bev-
acizumab.
Methods: Phase III trials, published since 1992, investigating ﬁrst line systemic treatment of Fédération
Internationale de Gynécologie et d'Obstétrique (FIGO) stage IIB-IV epithelial ovarian cancer were included. Since
most studies included patients with FIGO stage IV disease or incomplete debulking, all treatments were judged to
be palliative. Treatments were graded 5 to 1 on the ESMO-MCBSv1.1, where grades 5 and 4 represent a high
level of clinical beneﬁt.
Results: 55 studies met the inclusion criteria. ESMO-MCBS scores were calculated for eleven studies that showed
a statistically signiﬁcant beneﬁt of the experimental treatment. Intraperitoneal (ip) cisplatin scored a 4 and 3,
but two other studies were negative and therefore not scored on the ESMO-MCBS. Dose-dense paclitaxel showed
substantial clinical beneﬁt in one study (score 4), but three studies were negative. Addition of bevacizumab also
scored a 4 in one study subgroup including high-risk patients but a 2 in another trial with a larger study po-
pulation.
Conclusion: Based on ESMO-MCBS scores, dose-dense paclitaxel and intraperitoneal chemotherapy cannot be
recommended as standard treatment. Bevacizumab should be considered only in the high-risk population. The
ESMO-MCBSv1.1. helps to summarise reported studies on controversial treatment regimens, and identiﬁes their
weaknesses.
Introduction
Epithelial ovarian cancer has the highest mortality of all gynaeco-
logical cancers [1]. The disease is often diagnosed at a late stage be-
cause symptoms only develop once the disease has spread throughout
the abdominal cavity. However, even in case of advanced stage disease,
long-term survival is possible [2]. First line therapy for advanced dis-
ease consists of complete debulking surgery in combination with che-
motherapy (carboplatin and paclitaxel given every 3 weeks). Despite
extensive research, only few therapies with proven clinical beneﬁt have
been added to the therapeutic arsenal during the past decades (Fig. 1).
The total costs of ovarian cancer treatment have, however, increased
and vary greatly between European countries, partly due to diﬀerences
in use of both chemotherapeutic and targeted drugs [3,4]. European
Society of Medical Oncology (ESMO) clinical practice guidelines [5]
and National Comprehensive Cancer Network (NCCN) guidelines [6]
label several ﬁrst line therapies such as intraperitoneal (ip) cisplatin,
dose-dense weekly paclitaxel plus 3-weekly carboplatin, and bev-
azicumab maintenance therapy as ‘optional’. The recent debate on the
addition of bevacizumab to ﬁrst line treatment of advanced ovarian
cancer is exemplary for diﬀering policies between European countries
with respect to use of new drugs [7].
The inclusion of therapeutic strategies in health insurance plans and
health-care outcomes vary signiﬁcantly between countries [8–12].
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Some therapies provide only a small incremental beneﬁt despite risks of
serious toxicity. This makes careful consideration of their value for the
quality of life (QoL) of patients and health care costs for society es-
sential. ESMO has developed and validated a tool to assess the magni-
tude of clinical beneﬁt of cancer medicines: the Magnitude of Clinical
Beneﬁt Scale (MCBS) [13,14]. The aim of the ESMO-MCBS is to prior-
itise the most beneﬁcial treatments and make them available for all
patients in Europe. The ESMO-MCBS was designed to rank new drugs
based on adequately powered trials, taking into account diﬀerences in
study design and reported treatment eﬀects. Future anti-cancer drugs or
treatments that are approved by the European Medicines Agency (EMA)
will be evaluated using the ESMO-MCBS, and interventions showing
substantial beneﬁt will be highlighted in the ESMO guidelines. The
objective of this study was to re-evaluate the evidence regarding ﬁrst
line treatment of ovarian cancer using the ESMO-MCBSv1.1 with focus
on intraperitoneal chemotherapy, dose-dense paclitaxel and bev-
acizumab.
Methods
Search strategy and scoring
Published, phase III, randomised controlled trials (RCT’s) in-
vestigating ﬁrst line systemic treatment of Fédération Internationale de
Gynécologie et d'Obstétrique (FIGO) stage IIB-IV ovarian cancer were
identiﬁed by a PubMed search. The search terms used were: ovarian
neoplasms, ovarian cancer, drug therapy, chemotherapy, advanced
stage; results were ﬁltered for clinical trials on humans. References of
selected articles as well as the Cochrane Library Systematic Reviews
and the relevant international guidelines were cross-checked for addi-
tional published studies. Studies published from 1992, the introduction
of taxanes [15], until March 2018 were included. For studies reporting
impending long-term survival data, PubMed was additionally searched
speciﬁcally for publication of this data. The search was performed in-
dependently by two authors (MJ and KEB), in case of diﬀerent search
results these were discussed in the presence of a third investigator
(AKLR). For all studies reporting a statistically signiﬁcant beneﬁt of the
experimental treatment over the comparator, the magnitude of clinical
beneﬁt was scored by two separate authors (KEB and MJ) on the ESMO-
MCBSv1.1. In case of discussion or discrepancy between these two
authors’ scores, the judgment of a third author was decisive (AKLR). For
studies not reporting a statistically signiﬁcant beneﬁt of the study
treatment an ESMO-MCBS score could not be given.
ESMO-MCBS
The ESMO-MCBS [13,14] ranks the value of new cancer therapies in
a structured manner, by taking into account reported beneﬁts in terms
of longer survival (progression free survival (PFS), disease-free survival
(DFS), overall survival (OS)) and better survival (e.g. QoL, toxicity). To
make a comparison possible between trials with diﬀerent methods,
diﬀerent control groups and endpoints, there are separate scoring forms
divided by endpoint and duration of survival of the control group. First,
there are separate forms for curative (form 1) and palliative treatments
(form 2). Curative or adjuvant treatments are graded A, B or C, with
grade A and B corresponding to a substantial clinical beneﬁt. The
highest score (A) is given for> 5% improvement of OS at≥3 years, or
for improvement of DFS with a hazard ratio (HR) lower limit< 0.65
when mature survival data are lacking. For palliative treatments there
are forms for studies with a primary endpoint of OS (form 2a), PFS
(form 2b) or QoL, toxicity or response rate (RR) (form 2c). Palliative
treatments are graded 5 to 1, where grades 5 and 4 represent a sub-
stantial clinical beneﬁt. Recently, a revised version of the ESMO-MCBS
was published [14]. In ESMO-MCBSv1.1 a new form 3 was introduced
for scoring of single-arm studies in “orphan diseases” and for diseases
with “high unmet need” leading to registration of the treatment studied.
Furthermore, the threshold for absolute gain in median OS resulting in
a score of 5 or 4 was set higher (i.e. more conservative, at 9 months
instead of 5months) for studies with a median survival in the control
arm of more than 2 years. The preliminary score for palliative treat-
ments is upgraded when the study treatment shows an improvement in
QoL or a reduction in grade 3–4 toxicities impacting on daily well-
being. When PFS is the primary endpoint, the preliminary score is
downgraded when the study treatment has increased toxicity or does
not demonstrate improvement in QoL. All ESMO-MCBS forms can be
downloaded online (http://www.esmo.org/Policy/Magnitude-of-
Clinical-Beneﬁt-Scale).
It can be debated whether treatment of stage IV ovarian cancer,
with ﬁve-year overall survival of approximately 20%, should be con-
sidered curative or palliative. Cure rate depends on the amount of re-
sidual disease after surgery. This factor is highly variable, and besides
patient and tumour related factors, depends on the surgeon’s skills, the
location of treatment and the time period in which the study was per-
formed [16]. In this analysis, most studies included patients with stage
IV disease and allowed patients with residual masses after debulking
surgery to enter. Therefore, all treatments studied in the included trials
were labelled ‘with palliative intent’.
Validity of included studies
To evaluate the quality and robustness of the included studies and
compare studies with and without substantial beneﬁt on the ESMO-
MCBS, a Cochrane Institute validity checklist was used [17]. This
checklist is a synthesis of the Cochrane Collaboration risk of bias tool
[18] and contains ten items that are also included in the CONSORT
statement on reporting of RCTs [19] (Supplementary Table 1). It is
designed to visualise the validity of studies included in a systematic
review, but not to rank them based on a sum score. Weighing of the
Fig. 1. Evolution of standard ﬁrst line systemic therapy in advanced ovarian cancer.
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diﬀerent items is not incorporated in the checklist; hence there are no
threshold values for low or acceptable validity.
Results
The search resulted in 86 hits, of which 55 unique phase III trials
met the inclusion criteria. Of these studies, 44 investigated ﬁrst line
therapy and 11 investigated maintenance therapy after ﬁrst line
therapy. There were no single-arm trials leading to registration of the
studied treatment in advanced ovarian cancer. QoL data was available
for 18 of 55 included studies. Thirteen studies investigating ﬁrst line
treatment and one study on maintenance therapy showed a statistically
signiﬁcant beneﬁt of the experimental treatment. Three of these studies
reported a relative risk (RR) only and not a HR, therefore the ESMO-
MCBS score could not be calculated. As a result, ESMO-MCBS scoring
was performed for eleven of the 55 studies (Fig. 2).
Studies on controversial ﬁrst line treatments: Intraperitoneal chemotherapy,
dose-dense paclitaxel and bevacizumab
Table 1 shows the included studies on intraperitoneal che-
motherapy, dose-dense paclitaxel and bevacizumab. Studies showing
statistically signiﬁcant beneﬁt were scored using the ESMO-MCBSv1.1.
Ip administration of cisplatin achieved a score of 3 and 4 on ESMO-
MCBSv1.1 [20,21]. There were two negative studies on ip treatment
[22,23]. Dose dense administration of paclitaxel (80mg/m2 q1w)
compared to conventional dose paclitaxel (180mg/m2 q3w) is sup-
ported by one study (score 4) [24]. Three negative studies on weekly
paclitaxel were identiﬁed [25–27]. The addition of bevacizumab to
carboplatin and paclitaxel scored a 2 [28] and a 4 [29]. The score of 4
was achieved only in a high-risk population, deﬁned as stage IV disease,
inoperable stage III disease, or suboptimally debulked (> 1 cm) stage
III disease.
Standard of care options
The current standard ﬁrst line treatment with carboplatin and pa-
clitaxel is supported by ﬁve studies [30–34]. In these ﬁve studies car-
boplatin and paclitaxel were compared to cisplatin with or without
cyclophosphamide, the standard of care at that time. ESMO-MCBSv1.1
scores are 4, 4, 4, 3 and 4 respectively. Four of the studies showed
comparable survival but a better QoL [32] or toxicity proﬁle [30,31,33]
of the experimental treatment, one study showed an OS beneﬁt [34].
Other studies
Studies investigating other chemotherapeutic agents, anti-hormonal
therapy or immune modulating therapies did not show a statistically
signiﬁcant beneﬁt of the experimental treatment over the comparator,
nor a better QoL or toxicity proﬁle and are therefore not indicated in
the ﬁrst line treatment of ovarian cancer.
Of the 11 studies investigating maintenance therapy, only pazo-
panib maintenance treatment showed a statistically signiﬁcant beneﬁt
over the control arm (no maintenance treatment). However, the clinical
beneﬁt of maintenance therapy with pazopanib after surgical debulking
and ﬁrst line treatment with carboplatin and paclitaxel could not be
qualiﬁed as ‘substantial’, with a score of 2 [35].
Table 2 shows the 6 positive studies (5 carboplatin/paclitaxel and 1
pazopanib). All the negative studies on the current standard of care and
other treatment regimens are shown in Table 3 [36–71].
The three studies that did not report a HR are summarised in
Supplementary Table 2 [72–74]. It concerns one study comparing pa-
clitaxel/cisplatin to cyclophosphamide/cisplatin and two studies in-
vestigating ip cisplatin.
Validity of included studies
Validity scores of the 55 included phase III studies are shown in
Tables 4a and 4b. Nine studies fulﬁlled 5 or less of 10 criteria on the
Cochrane Institute checklist. Six of these were studies performed before
2000. One of these nine studies showed clinical beneﬁt of carboplatin
over cisplatin [31] while the other eight studies did not report clinically
meaningful beneﬁts of the experimental treatment. The studies sup-
porting ip administration of cisplatin score 6 out of 10 validity criteria
[20,21], as does one study supporting carboplatin over cisplatin added
to paclitaxel [33]. All the other studies scored on the ESMO-MCBSv1.1
fulﬁlled more than 6 validity criteria.
The two studies showing a statistically signiﬁcant beneﬁt of ip cis-
platin but not reporting a HR fulﬁlled 6/10 validity criteria
(Supplementary Table 3). Importantly, ip administration of cisplatin
was not the only diﬀerence between the control and the intervention
arm in these studies. Two doses of carboplatin were added to ip
Fig. 2. Flow diagram of studies included for analysis according to the ESMO-MCBSv1.1. RCT= randomised controlled trial; HR=hazard ratio.
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cisplatin and iv paclitaxel in the experimental arm in one study [72],
and in the other study an extra dose of paclitaxel was given per patient
in the intervention arm [73]. Two included negative studies (therefore
not scored on the ESMO-MCBSv1.1) on ip cisplatin treatment scored
low on the validity checklist: 4/10 and 5/10 [22,23].
Discussion
Based on ESMO-MCBS scores, intraperitoneal chemotherapy and
dose-dense paclitaxel cannot be recommended as standard treatment.
Addition of bevacizumab to ﬁrst line chemotherapy only showed sub-
stantial clinical beneﬁt in a high-risk subgroup of patients (stage IV
disease, inoperable stage III disease, or suboptimally debulked (> 1 cm)
stage III disease).
Ip chemotherapy using cisplatin does not provide substantial beneﬁt
as ﬁrst line treatment of advanced ovarian cancer according to the score
of 3 on the ESMO-MCBSv1.1 [20]. This is the only treatment with a
downgraded score (from 4 to 3) on v1.1 of the ESMO-MCBS compared
to v1.0. The diﬀerence between the two scores is due to the more re-
strictive criteria for ‘substantial beneﬁt’ on ESMO-MCBSv1.1 (absolute
gain ≥9months) compared to version 1.0 (absolute gain ≥5months)
[14]. Recently, the results of another study were published [21],
showing an improvement of recurrence-free survival (RFS) and OS of
the addition of hyperthermic intraperitoneal chemotherapy (HIPEC)
with cisplatin 100mg/m2 to interval debulking surgery in stage III
ovarian cancer patients not progressing after neo-adjuvant che-
motherapy. These outcomes give a score of ‘4’ on the ESMO-MCBS.
However, several questions remain, making these results mainly hy-
pothesis-generating and not yet practice-changing at this time [75]. It is
unclear whether the extra dose of cisplatin could have caused the ob-
served beneﬁts, and whether hyperthermia is essential for an eﬀect of ip
treatment. Furthermore, the results cannot be extrapolated to other
populations, such as stage IV patients, patients eligible for primary
debulking surgery or patients living in areas with less HIPEC experi-
ence. Ip cisplatin is mentioned as optional in guidelines, but it has not
been widely adopted. Arguable quality of the available evidence and
toxicity are the main arguments against use of ip chemotherapy in an
ongoing debate about this treatment modality [76]. OS-results of the
large GOG-252 trial comparing dose-dense iv paclitaxel, iv carboplatin
and iv bevacizumab (standard arm) to either dose-dense iv paclitaxel, ip
carboplatin and iv bevacizumab or iv paclitaxel q3w, ip cisplatin and ip
paclitaxel and iv bevacizumab are awaited. However, unfortunately, in
this study the treatment arms also diﬀer in more than one way im-
pairing validity [77].
Dose-dense administration of paclitaxel added to carboplatin pro-
vides substantial clinical beneﬁt in one study [24]. However, the re-
ported OS beneﬁt could not be conﬁrmed in a recent meta-analysis
including three analysed studies (not ICON8, only abstract available)
[78], and the three most recent studies on dose-dense paclitaxel showed
no PFS or OS-beneﬁt [25–27]. The positive study on dose-dense pacli-
taxel was conducted in a Japanese patient population. Survival is sug-
gested to be prolonged in Asian patients compared to Caucasian pa-
tients [79] potentially explained by genetic diﬀerences in drug
susceptibility [80]. This might explain the diﬀerent study results, and
this potential bias together with the burden of weekly hospital visits
and greater haematological toxicity, means that dose-dense paclitaxel
cannot be recommended as part of standard ﬁrst line treatment.
GOG-218 reports a beneﬁt of adding bevacizumab to ﬁrst line
treatment in ovarian cancer [28], however the score of 2 on the ESMO-
MCBSv1.1 does not qualify as ‘substantial improvement’ [13]. In ICON7
an OS beneﬁt for addition of bevacizumab was established in the sub-
group of patients at high risk of recurrence only (stage IV disease, in-
operable stage III disease, or suboptimally debulked (> 1 cm) stage III
disease). This prespeciﬁed subgroup analysis scored a ‘4’ [29]. Bev-
acizumab was approved as a component of ﬁrst line treatment by the
EMA based on the beneﬁt in these studies. However, in several
countries bevacizumab has not been introduced in ﬁrst line ovarian
cancer treatment due to lack of data showing a consistent improvement
in OS, concerns about gastro-intestinal toxicity and lack of cost-eﬀec-
tiveness.
The current, post-surgical, standard ﬁrst line treatment of advanced
ovarian cancer, combination chemotherapy with carboplatin and pa-
clitaxel, is strongly supported by four studies that score a substantial
clinical beneﬁt on the ESMO-MCBSv1.1 [30–32,34]. There are two
studies that did not show clinical beneﬁt of paclitaxel added to pla-
tinum compared to platinum monotherapy [41,42]. Possible explana-
tions are cross-over of about 30% from the monotherapy to the com-
bination therapy arm, and a higher dose-intensity of carboplatin in the
monotherapy arm of both studies. The largest meta-analysis of diﬀerent
chemotherapeutic schedules in advanced ovarian cancer (60 trials with
survival endpoints, N= 15609 women) did show a survival beneﬁt of
combination therapy with a platinum and a taxane over platinum
monotherapy. This meta-analysis did not only include phase III trials on
ﬁrst line treatment, but also randomised phase II trials and studies on
second and third line treatment [81].
Pazopanib maintenance therapy showed clinical beneﬁt based on
improvement of PFS. However, due to excess toxicity leading to early
treatment discontinuation in nearly one third of the patients, especially
in the Asian population, pazopanib did not go into further development
in the treatment of ovarian cancer [80,82].
The ESMO-MCBSv1.1 score can only be calculated when there is
input of correct data. The ﬁrst step in using the ESMO-MCBSv1.1 is
selection of the most appropriate scoring form, by labelling the goal of
the studied treatment as either curative or palliative. All treatments
studied in the included trials were labelled ‘with palliative intent’.
However, the aforementioned criteria used to label a treatment as ‘with
curative’ or ‘palliative intent’ are arbitrary and not evidence based.
Seven of the studies included [24,25,33,36,58,72,73] speciﬁed multiple
primary endpoints but were powered for only one, and ﬁve studies
[22,45,58,65,74] did not report any power analysis. For one study [41]
presented as an equivalence study a non-inferiority design was not re-
ported, therefore scoring on the ESMO-MCBSv1.1 could not be ade-
quately performed. Studies from the past 25 years were included in this
analysis. Surgery, but also supportive care including anti-emetics and
analgesics have changed over these years. This might inﬂuence the
comparison of treatment results in this long time period. Current
standards for study design are more robust with clear-cut guidelines for
reporting results, such as hazard ratios [83]. A recent analysis of 226
contemporary RCTs showed that only one third of modern studies were
designed to detect an eﬀect size meeting the ESMO-MCBSv1.0 thresh-
olds [84]. The current analysis includes studies with methodological
shortcomings. To take into account the validity of the included studies
we used a Cochrane Institute checklist for RCTs. For the six included
studies on ip chemotherapy these validity scores clearly illustrate the
suboptimal methodological quality of these studies. These study design
weaknesses have provoked much of the debate on this treatment
strategy. QoL data was only available for 18 of 55 included studies.
Palliative studies showing a beneﬁt in PFS but comparable QoL are
downgraded one point (form 2B). This makes reporting of QoL data less
attractive if no beneﬁt in this endpoint is established. QoL and toxicity
are especially important in treatments that are likely palliative, such as
in advanced ovarian cancer. Palliative treatments showing non-inferior
survival but reduced toxicity can score a ‘4’ on the ESMO-MCBSv1.1
(form 2c). However, reduced toxicity is not clearly deﬁned and the
relative weight attributed to diﬀerent toxicities remains subjective. This
is a part of the ESMO-MCBS that could be further elaborated.
Recently, several other methods have been developed to determine
the clinical beneﬁt of cancer treatments. The American Society of
Clinical Oncology (ASCO) published the ASCO Value Framework, a tool
which incorporates clinical beneﬁt, toxicity and also treatment costs
[85]. Since the costs of the treatments in the included trials vary be-
tween countries, this tool was not used in the current analysis. Another































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Cochrane Institute checklist for validity scores of trials on ip chemotherapy,
dose-dense paclitaxel and bevacizumab. Corresponding question Cochrane va-
lidity checklist answered with: √=yes, –=no, ?= unknown (question not
answered in referred publication).
Study Power analysis Validity items
1 2 3 4 5 6 7 8 9 10 Total
Intraperitoneal chemotherapy
Alberts [20] √ √ ? – – √ √ √ √ √ – 6
van Driel [21] √ √ ? – – √ √ √ – √ √ 6
Kirmani [22] – √ √ – – √ – – – √ – 4
Gadducci [23] √ √ √ – – – – √ √ √ – 5
Dose-dense paclitaxel
JGOG 3016 [24] √ √ √ – – √ √ √ √ √ √ 8
Pignata [25] √ √ √ – ? √ √ √ √ √ √ 8
Chan [26] √ √ ? – ? √ √ √ √ – – 5
ICON8 [27] Trial results not published
Bevacizumab
GOG 218 [28] √ √ √ √ √ √ √ √ √ √ – 9
ICON7 2015 [29] √ √ √ – – √ √ √ √ √ – 7
Table 4b
Cochrane Institute checklist for validity scores of trials on other treatments.
Corresponding question Cochrane validity checklist answered with: √=yes,




1 2 3 4 5 6 7 8 9 10 Total
Hannigan [30] √ √ √ – – √ √ √ √ √ ? 7
Taylor [31] √ √ ? – – √ √ ? √ √ ? 5
Du Bois [32] √ √ √ – – √ √ √ √ √ – 7
Ozols [33] √ √ √ – – √ √ √ – √ ? 6
Piccart [34] √ √ √ – – √ √ √ √ √ – 7
Du Bois [35] √ √ √ √ √ √ √ √ √ √ – 9
Swenerton [36] √ √ √ – – √ √ √ √ √ – 7
Meerpohl [37] √ √ ? – – – √ – – √ – 3
Neijt [38] √ √ ? – – √ √ √ √ √ – 6
Aravantinos [39] √ √ ? – – √ – √ √ √ – 5
SCOTROC4 [40] √ √ √ – – √ √ √ √ √ √ 8
GOG 132 [41] √ √ √ – – – √ √ – √ √ 6
ICON3 [42] √ √ √ – – √ √ √ √ √ √ 8
Spriggs [43] √ √ √ – – √ √ √ √ √ – 7
Skarlos [44] √ √ √ – – √ √ √ √ √ – 7
Wadler [45] – √ ? – – √ √ √ – √ ? 5
Wils [46] √ √ ? ? ? – √ √ – √ – 4
SCOTROC1 [47] √ √ √ – – √ √ √ √ – – 6
Du Bois 2006 [48] √ √ √ – – √ √ √ √ √ – 7
HIDOC-EIS [49] √ √ ? – – √ √ √ √ √ – 6
ICON5 [50] √ √ √ – – √ √ √ – √ – 6
Bolis [51] √ √ √ – – √ √ – √ √ – 6
Du Bois 2010 [52] √ √ √ – – √ √ √ √ √ – 7
Hoskins [53] √ √ √ – – √ √ √ √ √ √ 8
MITO-2 [54] √ √ √ – – √ √ √ √ √ – 7
Fruscio [55] √ √ ? – – √ √ √ √ √ ? 6
Lindemann [56] √ √ √ – – √ √ √ √ √ – 7
Emons [57] √ √ √ √ √ √ √ – √ √ – 8
Windbichler [58] – √ √ – – √ √ √ √ √ – 7
Alberts 2008 [59] √ √ √ – – √ √ √ √ √ – 7
Lhommé [60] √ √ √ – – √ √ √ – √ – 6
AGO-OVAR12 [61] √ √ √ √ √ √ √ √ √ – – 8
EORTC 55875 [62] √ √ ? – – √ √ √ √ √ – 6
Markman [63] √ √ ? – – √ √ √ √ √ – 6
MITO-1 [64] √ √ √ – – √ √ √ √ √ – 7
Nicoletto [65] – √ ? – – – √ √ √ √ – 5
Hall [66] √ √ √ – – √ √ √ √ √ – 7
Alberts 2006 [67] √ √ √ – – √ √ √ √ √ – 7
Hirte [68] √ √ √ √ ? √ √ √ √ √ – 8
Pecorelli [69] √ √ √ – – √ √ √ √ √ – 7
Berek [70] √ √ √ √ √ √ √ – √ √ – 8
MIMOSA [71] √ √ √ √ √ √ √ √ √ √ – 9
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example are the NCCN Evidence Blocks developed to visualise the key
measures that form the basis of the recommendations in the NCCN
clinical practice guidelines [86].
A major caveat is that ESMO-MCBSv1.1 scores are only calculated
for studies showing either a statistically signiﬁcant survival beneﬁt of
the studied treatment, or non-inferior survival but better QoL or less
clinically signiﬁcant grade 3–4 toxicities. Negative studies could be
overlooked in treatment advices and guidelines, because of this selec-
tion bias. However, keeping this in mind, summarising the clinical
beneﬁt of diﬀerent treatment strategies using the ESMO-MCBS does
provide a quick overview of the available body of evidence. A com-
parable analysis of second and third line treatments could therefore be
considered.
Conclusion and future perspectives
Based on ESMO-MCBS scores, dose-dense paclitaxel and in-
traperitoneal chemotherapy cannot be recommended as standard ﬁrst
line treatment in advanced ovarian cancer. Bevacizumab can be con-
sidered in the high-risk population, but is debated because an OS
beneﬁt was only shown in this subgroup of patients. The current stan-
dard ﬁrst line treatment in advanced ovarian cancer, combination
chemotherapy with carboplatin and paclitaxel, is strongly supported by
ranking of the available evidence on the ESMO-MCBSv1.1. ESMO-
MCBSv1.1 thresholds for clinical beneﬁt, including QoL analyses and
reporting of hazard ratios, should be taken into account in designing
future clinical trials.
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